04:14 AM EDT, 08/13/2026 (MT Newswires) -- AbCellera Biologics ( ABCL ) priced a public offering of shares and pre-funded warrants for expected gross proceeds of about $200 million, the company said Thursday.

The offering consists of about 17.4 million shares priced at $9.75 each and pre-funded warrants to purchase up to about 3.1 million shares at $9.74999 per warrant.

The offering is expected to close Friday.

The company intends to use the net proceeds to fund research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and general corporate purposes.